Firefly Neuroscience (AIFF)

Firefly’s principal product is its Brain Network Analytics, or BNA, software platform. The BNA Platform analyzes brain activity data and is designed to identify patterns that may be relevant to diagnosis, treatment selection, monitoring or clinical research. By applying AI and data analytics to neurophysiological signals, the company aims to give healthcare professionals a clearer view of how a patient’s brain networks are operating, rather than relying only on subjective symptoms or standard clinical questionnaires.

The company also works on biomarker discovery and clinical development. In neuroscience, biomarkers can be valuable because mental health and cognitive conditions are often complex, heterogeneous and difficult to measure objectively. Firefly’s approach seeks to connect data-driven brain measurements with patient outcomes, potentially supporting more personalized care and more efficient development of therapies.

Firefly Neuroscience reports its business through one operating segment, the BNA platform, and generates revenue in North America. As a listed company, it offers investors exposure to the emerging field of AI-enabled neuroscience. Its opportunity is tied to the adoption of objective brain-function analytics by clinicians, researchers and healthcare systems, as well as the continued validation of its technology in medical and scientific settings.